CXCL12 signaling is independent of Jak2 and Jak3

被引:33
|
作者
Moriguchi, M
Hissong, BD
Gadina, M
Yamaoka, K
Tiffany, HL
Murphy, PM
Candotti, F
O'Shea, JJ
机构
[1] NIAMS, Mol Immunol & Inflammat Branch, NIH, Bethesda, MD 20892 USA
[2] NIAID, Host Def Lab, NIH, Bethesda, MD 20892 USA
[3] NHGRI, Genet & Mol Biol Branch, NIH, Bethesda, MD 20892 USA
关键词
D O I
10.1074/jbc.M414219200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Janus kinases (Jaks) are a small family of cytoplasmic tyrosine kinases, critical for signaling by Type I and II cytokine receptors. The importance of Jaks in signaling by these receptors has been firmly established by analysis of mutant cell lines, the generation of Jak knock-out mice, and the identification of patients with Jak3 mutations. While a number of other ligands that do not bind Type I and II cytokine receptors have also been reported to activate Jaks, the requirement for Jaks in signaling by these receptors is less clear. Chemokines for example, which bind seven transmembrane receptors, have been reported to activate Jaks, and principally through the use of pharmacological inhibitors, it has been argued that Jaks are essential for chemokine signaling. In the present study, we focused on CXCR4, which binds the chemokine CXCL12 or stromal cell-derived factor-1, a chemokine that has been reported to activate Jak2 and Jak3. We found that the lack of Jak3 had no effect on CXCL12 signaling or chemotaxis nor did overexpression of wild-type versions of the kinase. Similarly, overexpression of wild-type or catalytically inactive Jak2 or "knocking-down" Jak2 expression using siRNA also had no effect. We also found that in primary lymphocytes, CXCL12 did not induce appreciable phosphorylation of any of the Jaks compared with cytokines for which these kinases are required. Additionally, little or no Stat ( signal transducer and activator of transcription) phosphorylation was detected. Thus, we conclude that in contrast to previous reports, Jaks, especially Jak3, are unlikely to play an essential role in chemokine signaling.
引用
收藏
页码:17408 / 17414
页数:7
相关论文
共 50 条
  • [1] CXCL12 signaling is independent of Jak3.
    Moriguchi, M
    Gadina, M
    Tiffany, L
    Murphy, PM
    O'Shea, JJ
    ARTHRITIS AND RHEUMATISM, 2002, 46 (09): : S256 - S256
  • [2] CXCL12 Regulates through JAK1 and JAK2 Formation of Productive Immunological Synapses
    Cascio, Graciela
    Martin-Cofreces, Noa B.
    Miguel Rodriguez-Frade, Jose
    Lopez-Cotarelo, Pilar
    Criado, Gabriel
    Pablos, Jose L.
    Luis Rodriguez-Fernandez, Jose
    Sanchez-Madrid, Francisco
    Mellado, Mario
    JOURNAL OF IMMUNOLOGY, 2015, 194 (11): : 5509 - 5519
  • [3] Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor
    Alfonso Quintás-Cardama
    Taghi Manshouri
    Zeev Estrov
    David Harris
    Ying Zhang
    Amos Gaikwad
    Hagop M. Kantarjian
    Srdan Verstovsek
    Investigational New Drugs, 2011, 29 : 818 - 826
  • [4] Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor
    Quintas-Cardama, Alfonso
    Manshouri, Taghi
    Estrov, Zeev
    Harris, David
    Zhang, Ying
    Gaikwad, Amos
    Kantarjian, Hagop M.
    Verstovsek, Srdan
    INVESTIGATIONAL NEW DRUGS, 2011, 29 (05) : 818 - 826
  • [5] RANTES activates Jak2 and Jak3 to regulate engagement of multiple signaling pathways in T cells
    Wong, M
    Uddin, S
    Majchrzak, B
    Huynh, T
    Proudfoot, AEI
    Platanias, LC
    Fish, EN
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (14) : 11427 - 11431
  • [6] Molecular Dynamics Simulation of the Selectivity of Fedratinib Complex with JAK2/JAK3
    Liu Haichun
    Lu Shuai
    Zhang Yanmin
    Zhou Weineng
    Yin Lingfeng
    Zhu Lu
    Zhao Junnan
    Lu Tao
    Chen Yadong
    CHEMICAL JOURNAL OF CHINESE UNIVERSITIES-CHINESE, 2018, 39 (07): : 1540 - 1548
  • [7] Selective Downregulation of JAK2 and JAK3 by an ATP-Competitive pan-JAK Inhibitor
    Field, S. Denise
    Arkin, Jacob
    Li, Jing
    Jones, Lyn H.
    ACS CHEMICAL BIOLOGY, 2017, 12 (05) : 1183 - 1187
  • [8] Design of JAK3 covalent inhibitors for the interrogation of JAK3 signaling in humans
    Casimiro-Garcia, Agustin
    Thorarensen, Atli
    Telliez, Jean-Baptiste
    Balbo, Paul
    Banker, Mary
    Brown, Matthew
    Che, Ye
    Chrencik, Jill
    Coe, Jotham
    Czerwinski, Robert
    Dowty, Martin
    Gilbert, Adam
    Hayward, Matthew
    Hegen, Martin
    Juba, Brian
    Jussif, Jason
    Langille, Jonathan
    Leung, Louis
    Liang, Sidney
    Lin, Tsung
    Montgomery, Justin
    Soucy, Sarah
    Trujillo, John
    Unwalla, Ray
    Vajdos, Felix
    Vincent, Fabien
    Yang, Xin
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 253
  • [9] Pyrrolo[1,2-f]triazines as JAK2 inhibitors: Achieving potency and selectivity for JAK2 over JAK3
    Harikrishnan, Lalgudi S.
    Kamau, Muthoni G.
    Wan, Honghe
    Inghrim, Jennifer A.
    Zimmermann, Kurt
    Sang, Xiaopeng
    Mastalerz, Harold A.
    Johnson, Walter L.
    Zhang, Guifen
    Lombardo, Louis J.
    Poss, Michael A.
    Trainor, George L.
    Tokarski, John S.
    Lorenzi, Matthew V.
    You, Dan
    Gottardis, Marco M.
    Baldwin, Kathy F.
    Lippy, Jonathan
    Nirschl, David S.
    Qiu, Ruhui
    Miller, Arthur V.
    Khan, Javed
    Sack, John S.
    Purandare, Ashok V.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (05) : 1425 - 1428
  • [10] Inhibitors of JAK2 and JAK3: an update on the patent literature 2010-2012
    Dymock, Brian W.
    See, Cheng Shang
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2013, 23 (04) : 449 - 501